Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

Diabetes Care

Volumn 20, Issue 5, 1997, Pages 735-744

  Eastman, Richard C ^a   Javitt, Jonathan C ^b   Herman, William H ^c   Dasbach, Erik J ^e   Copley Merriman, Catherine ^d   Maier, William ^d   Dong, Fred ^f   Manninen, Diane ^f   Zbrozek, Arthur S ^g   Kotsanos, James ^h   Garfield, Sanford A ^a   Harris, Maureen ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d PFIZER INC   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Bauelle Inc   (United States)

^g BAYER CORPORATION   (United States)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE;

EID: 15644366137     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.5.735     Document Type: Article

References (47)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
3. Klein R, Klein BEK: Vision disorders in diabetes. In Diabetes in America. 2nd ed. National Diabetes Data Group, Eds. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, p. 293-338 (NIH publ. no. 95-1468)
4. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
5. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study (UKPDS). Diabetologia 34:877-890, 1991
6. The U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
7. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Johnson Nagel N, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS, VA CSDM Group: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care 18:1113-1123, 1995
8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
9. American Diabetes Association: Metabolic control matters: nationwide translation of the Diabetes Control and Complications Trial: analysis and recommendations. Clin Diabetes 11:91,95-96, 1993
10. Clark CM, Vinicor F: Introduction: risks and benefits of intensive management in non-insulin-dependent diabetes mellitus: the Fifth Regenstrief Conference. Ann Intern Med 124:81-85, 1996
11. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 19 (Suppl. 1):S8-S15, 1996
12. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, Manninen D, Garfield SA, Copley-Merriman C, Maier W, Eastman JF, Kotsanos J, Cowie CC, Harris M: Model of complications of NIDDM: I. Model construction and assumptions. Diabetes Care 20:725-734
13. Harris M, Flegal K, Cowie C, Eberhardt M: Glycemic control of adults with diagnosed diabetes in the U.S (Abstract). Diabetes 45 (Suppl. 2):122A, 1996
14. DeFronzo RA, Goodman AM: The Multicenter Metformin Study Group: efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
15. Javitt JC, Aiello LP, Chiang Y, Ferris RL III, Canner JK, Greenfield S: Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health-care reform. Diabetes Care 17:909-917, 1994
16. Brechner RJ, Cowie CC, Howie LJ, Herman WH, Will JC, Harris MI: Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA 270:1714-1718, 1993
17. The DCCT Study Group: Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 18:1468-1478, 1995
18. Chiang YP, Bassi LJ, Javitt JC: Federal budgetary costs of blindness. Millbank Q 70: 319-340, 1992
19. Striker GA: Report on a workshop to develop management recommendations for the prevention and progression in chronic renal disease. J Am Soc Nephrol 5:1537-1540, 1995
20. Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan S, Sullivan E, Dukes K, Pauker SG: Foot infections in diabetic patients. JAMA 273:712-720, 1995
21. DCCT Study Group: Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial: an economic evaluation. JAMA. 276:1409-1415, 1996
22. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Faergeman D, Thorgeirsson G, Jonsson B, Schwartz JS: Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 93:1796-1802, 1996
23. Fertig BJ, Simmons DA, Martin DB: Therapy for diabetes. In Diabetes in America. 2nd ed. National Diabetes Data Group, Eds. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, p. 519-540 (NIH publ. no. 95-1468)
24. Harris MI, Eastman RC, Siebert C: The DCCT and medical care for diabetes in the US. Diabetes Care 17:761-764, 1994
25. Medical Economics: Redbook 1995. Montvale, NJ, Medical Economics, 1995
26. Javitt JC, Chiang Y-P: Economic impact of diabetes. In Diabetes in America. 2nd ed. National Diabetes Data Group, Eds. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, p. 601-612 (NIH publ. no. 95-1468)
27. Medicare: Average allowed charge for Medicare Part B in 1994 for CPT-4 codes 99211, 99212, 99213, 99214, and 99215 office visits. Washington, DC, Health Care Financing Administration, 1994
28. Weinstein MC, Stason WB: Foundations of cost-effectiveness for health and medical practices. N Engl J Med 296:716-721, 1977
29. Eisenberg JM: Clinical economics: a guide to the economic analysis of clinical practices. JAMA 262:2879-2886, 1989
30. Dasbach EJ, Fryback DG, Thornbury JR: Health utility preference differences (Abstract). Med Decis Making 12:4, 1992
31. Gorsky RD, Teutsch SM: Assessing the effectiveness of disease and injury prevention programs: costs and consequences. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. MMWR 44:1-10, 1995
32. National Diabetes Information Clearinghouse: Diabetes Statistics. Bethesda, MD, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1994 (Publ. 94-3822)
33. Geiss LS, Herman WH, Smith PJ: Mortality in non-insulin-dependent diabetes. In Diabetes in America. 2nd ed. National Diabetes Data Group, Eds. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, p. 233-258 (NIH publ. no. 95-1468)
34. Sievers ML, Nelson RG, Knowler WC, Bennett PH: Impact of NIDDM on the mortality and causes of death in Pima Indians. Diabetes Care 15:1541-1549, 1992
35. Ballard DJ, Humphrey LL, Melton J III, Frohnert PP, Chu C-P, O'Fallon WM, Palumbo PJ: Epidemiology of persistent proteinuria in type II diabetes mellitus. Diabetes 37:405-412, 1988
36. Palumbo P: Diabetes Control and Complications Trial: the continuing challenge ahead (Editorial). Mayo Clin Proc 68:1126-1127, 1993
37. Lasker RD: The Diabetes Control and Complications Trial: implications for policy and practice (Editorial). N Engl J Med 329: 1035-1036, 1993
38. Eastman RC, Siebert CS, Harris M, Gorden P: Clinical Review 51: implications of the Diabetes Control and Complications Trial. J Clin Endocrinol Metab 77:1105-1107, 1993
39. Eastman RC, Gorden P: The DCCT: implications for diabetes treatment. Diabetes Rev 2:263-271, 1994
40. Nathan DM: Inferences and implications: do results from the Diabetes Control and Complications Trial apply in NIDDM? Diabetes Care 2:251-257, 1995
41. Andersson DKG, Svardsudd K: Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534-1543, 1995
42. Coniff RF, Shapiro JA, Seaton TB, Bray GA: Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98:443-451, 1995
43. Wingard DL, Barrett-Connor E: Diabetes in America. 2nd ed. National Diabetes Data Group, Eds. Heart Disease and Diabetes Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, p. 429-448 (NIH publ. no. 95-1468)
44. Abraira C, Maki KC: Does insulin treatment increase cardiovascular risk in NIDDM. Clin Diabetes 13:29-31, 1995
45. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study). J Am Coll Cardiol 26:57, 1995
46. Mason J: Some guidelines on the use of cost effectiveness league tables. BMJ 306:507-572, 1993
47. Stason WB: Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol. Am Heart J 119:18-24, 1990